Quinolone derivatives as antitubercular drugs

Medicinal Chemistry Research

Volumn 22, Issue 3, 2013, Pages 1029-1042

  Asif, Mohammad ^a   Siddiqui, Anees A ^b   Husain, Asif ^b  

^a Guru Ram das (PG) Institute of Management and Technology   (India)

^b HAMDARD UNIVERSITY   (India)

Author keywords

Chemotherapeutic agents; Multidrug resistant; Quinolones; Tuberculosis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CINOXACIN; CIPROFLOXACIN; CYCLOSERINE; DIHYDROSTREPTOMYCIN; ETHIONAMIDE; GATIFLOXACIN; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; OXOLINIC ACID; PEFLOXACIN; PROTIONAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; SPARFLOXACIN; STREPTOMYCIN; TEMAFLOXACIN; THIORIDAZINE; TROVAFLOXACIN; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; VIOMYCIN;

ACUTE SINUSITIS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CHRONIC BRONCHITIS; COMBINATION CHEMOTHERAPY; COMMUNITY ACQUIRED PNEUMONIA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG STRUCTURE; GRAM NEGATIVE INFECTION; HEART ARRHYTHMIA; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; MONOTHERAPY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; QT PROLONGATION; REVIEW; SINGLE DRUG DOSE; SKIN INFECTION; SOFT TISSUE INFECTION; TUBERCULOSIS; URINARY TRACT INFECTION;

EID: 84874112020     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-012-0101-3     Document Type: Review

References (88)

1. Alangaden GJ, Lerner SA (1997) The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin Infect Dis 25:1213-1221
2. Alangaden GJ, Manavathu EK, Vakulenko SB, Zvonok NM, Lerner SA (1995) Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients. Antimicrob Agents Chemother 39:1700-1703
3. Al-Deeb AO, Alafeefy AM (2008) Synthesis of some new 3H-quinazolin-4-one derivatives as potential antitubercular agents. World Appl Sci J 5(1):94-99
4. Alvirez-Freites EJ, Carter JL, Cynamon MH (2002) In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 46:1022-1025
5. Aubry A, Pan XS, Fisher LM, Jarlier V, Cambau E (2004) Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob Agents Chemother 48:1281-1288
6. Bagchi MC, Mills D, Basak SC (2007) Quantitative structure-activity relationship (QSAR) studies of quinolone antibacterials against M. fortuitum and M. smegmatis using theoretical molecular descriptors. J Mol Model 13:111-120
7. Barman Balfour JA, Lamb HM (2000) Moxifloxacin. A review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs 59(1):115-139
8. Bertino J Jr, Fish D (2000) The safety profile of the fluoroquinolones. Clin Ther 22(7):798-817
9. Biedenbach DJ, Sutton LD, Jones RN (1995) Antimicrobial activity of CS-940, a new trifluorinated quinolone. Antimicrob Agents Chemother 39(10):2325-2330
10. Bozeman L, Burman W, Metchock B, Welch L, Weiner M (2005) Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada. Clin Infect Dis 40:386-391
11. Brenwald NP, Gill MJ, Wise R (1998) Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 42:2032-2035
12. Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, Choudhri S, Daley CL, Munsiff SS, Zhao Z et al (2006) Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 174:331-338
13. CDC (2006) Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 55:301-305
14. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163:1009-1021
15. Coyle EA, Kaatz GW, Rybak MJ (2001) Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 45:1654-1659
16. Cynamon MH, Sklaney M (2003) Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis. Antimicrob Agents Chemother 47:2442-2444
17. Daffe M, Brennan PJ, Mcneil M (2007) Predominant structural features of the cell wall arabinogalactan of Mycobacterium tuberculosis as revealed through characterization. J Med Chem 50:2492
18. Daporta MT, Munoz Bellido JL, Guirao GY, Hernandez MS, Garcia-Rodriguez JA (2004) In vitro activity of older and newer fluoroquinolones against efflux-mediated high level ciprofloxacinresistant Streptococcus pneumoniae. Int J Antimicrob Agents 24:185-187
19. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC (1999) Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA 282:677-686
20. Flamm RK, Vojtko C, Chu DT, Li Q, Beyer J, Hensey D, Ramer N, Clement JJ, Tanaka SK (1995) In vitro evaluation of ABT-719, a novel DNA gyrase inhibitor. Antimicrob Agents Chemother 39:964-970
21. Flynn JL, Chan J (2001) Tuberculosis: latency and reactivation. Infect Immun 69:4195-4201
22. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C (2003) Tuberculosis. Lancet 362:887-899
23. Garay SM (2004) Pulmonary tuberculosis. In: Rom WN, Garay SM (eds) Tuberculosis. Lippincott Williams & Wilkins, Philadelphia, pp 345-394
24. Ginsburg AS, Grosset JH, Bishai WR (2003a) Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 3:432-442
25. Ginsburg AS, Hooper N, Parrish N, Dooley KE, Dorman SE, Booth J, Diener-West M, Merz WG, Bishai WR, Sterling TR (2003b) Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis 37:1448-1452
26. Ginsburg AS, Sun R, Calamita H, Scott CP, Bishai WR, Grosset JH (2005) Emergence of fluoroquinolone resistance in Mycobacterium tuberculosis during continuously dosed moxifloxacin monotherapy in a mouse model. Antimicrob Agents Chemother 49:3977-3979
27. Glickman SW, Rasiel EB, Hamilton CD, Kubataev A, Schulman KA (2006) Medicine. A portfolio model of drug development for tuberculosis. Science 311:1246-1247
28. Global Alliance for TB Drug Development (2001) Tuberculosis. Scientific blue print for tuberculosis drug development. Tuberculosis (Edinb) 81(Suppl 1):1-52
29. Gomez JE, McKinney JD (2004) M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb) 84:29-44
30. Grosset JH (1992) Treatment of tuberculosis in HIV infection. Tuber Lung Dis 73:378-383
31. Grosset J, Ji B (1998) Experimental chemotherapy of mycobacterial diseases. In: Gangadharam PRJ, Jenkins PA (eds) Mycobacteria, II chemotherapy. Chapman & Hall, New York, pp 51-97
32. Grosset J, Truffot-Pernot C, Lacroix C, Ji B (1992) Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother 36:548-551
33. Herbert D, Paramasivan CN, Venkatesan P, Kubendiran G, Prabhakar R, Mitchison DA (1996) Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother 40:2296-2299
34. ID Weekly Highlights (2000) Moxifloxacin: a new antimicrobial agent. Presented at the 40th CAAC Meeting, Toronto, and September 17-20, 2000. Reported by Pireh D, October, 32-33
35. Hirata T, Saito H, Tomioka H, Sato K, Jidoi J, Hosoe K, Hidaka T (1995) In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 39:2295-2303
36. Hong Kong Chest Service/British Medical Research Council (1992) A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Tuber Lung Dis 73:59-67
37. Houston AK, Jones RN (1994) Postantibiotic effect of DU-6859a and levofloxacin as compared with ofloxacin. Diagn Microbiol Infect Dis 18(1):57-59
38. Hu Y, Coates AR, Mitchison DA (2003) Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 47:653-657
39. Islam M, Siddiqui AA, Rajesh R (2008) Synthesis, antitubercular, antifungal and antibacterial activities of 6-substituted phenyl-2-(3í- substituted phenyl pyridazin-6í-yl)-2,3,4,5-tetrahydropyridazin-3-one. Acta Pol Pharm 65(3):353-362
40. Jones PB, Parrish NM, Houston TA, Stapon A, Bansal NP, Dick JD, Townsend CA (2000) A new class of antituberculosis agents. J Med Chem 43:3304-3314
41. Kamal A, Azeeza S, Malik MS, Shaik AA, Rao MV (2008) Efforts towards the development of new antitubercular agents: potential for thiolactomycin based compounds. J Pharm Pharmaceut Sci 11(2):56s-80s
42. Kaufmann SH, Cole ST, Mizrahi V, Rubin E, Nathan C (2005) Mycobacterium tuberculosis and the host response. J Exp Med 201:1693-1697
43. Khasnobis S, Escuyer VE, Chatterjee D (2002) Emerging therapeutic targets in tuberculosis: post genomic era. Expert Opin Ther Targ 6:21-40
44. Klemens SP, DeStefano MS, Cynamon MH (1993) Therapy of multidrug-resistant tuberculosis: lessons from studies with mice. Antimicrob Agents Chemother 37:2344-2347
45. Kocagoz T, Hackbarth CJ, Unsal I, Rosenberg EY, Nikaido H, Chambers HF (1996) Gyrase mutations in laboratory-selected, fluoroquinoloneresistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother 40:1768-1774
46. Koga T, Fukuoka T, Doi N, Harasaki T, Inoue H, Hotoda H, Kakuta M, Muramatsu Y, Yamamura N, Hoshi M, Hirota T (2004) Activity of capuramycin analogues against Mycobacterium tuberculosis Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo. J Antimicrob Chemother 54:755-760
47. Kunin CM, Ellis WY (2000) Antimicrobial activities of mefloquine and a series of related compounds. Antimicrob Agents Chemother 44(4):848-852
48. Lenaerts AJ, Gruppo V, Marietta KS, Johnson CM, Driscoll DK, Tompkins NM, Rose JD, Reynolds RC, Orme IM (2005) Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 49:2294-2301
49. Lewin CS, Howard BM, Smith JT (1991) 4-Quinolone interactions with gyrase subunit B inhibitors. J Med Microbiol 35:358-362
50. Li XZ, Zhang L, Nikaido H (2004) Efflux pump-mediated intrinsic drug resistance in Mycobacterium smegmatis. Antimicrob Agents Chemother 48:2415-2423
51. Manabe YC, Bishai WR (2000) Latent Mycobacterium tuberculosis- persistence, patience, and winning by waiting. Nat Med 6:1327-1329
52. Miyazaki E, Miyazaki M, Chen JM, Chaisson RE, Bishai WR (1999) Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother 43:85-89
53. Murugasu-Oei B, Dick T (2000) Bactericidal activity of nitrofurans against growing and dormant Mycobacterium bovis BCG. J Antimicrob Chemother 46:917-919
54. Nikonenko BV, Samala R, Einck L, Nacy CA (2004) Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis. Antimicrob Agents Chemother 48:4550-4555
55. Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, Chaisson RE, Bishai WR, Grosset JH (2004a) Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 169:421-426
56. Nuermberger EL, Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, O'Brien RJ, Vernon AA, Chaisson RE, Bishai WR, Grosset JH (2004b) Moxifloxacin- containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 170:1131-1134
57. O'Brien RJ, Nunn PP (2001) The need for new drugs against tuberculosis. Obstacles, opportunities, and next steps. Am J Respir Crit Care Med 163:1055-1058
58. Onodera Y, Tanaka M, Sato K (2001) Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis. J Antimicrob Chemother 47:447-450
59. Paramasivan CN, Sulochana S, Kubendiran G, Venkatesan P, Mitchison DA (2005) Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother 49:627-631
60. Pasqualoto KFM, Ferreira EI (2001) An approach for the rational design of new antituberculosis agents. Curr Drug Targets 2:427-437
61. Pestova E, Millichap JJ, Noskin GA, Peterson LR (2000) Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J Antimicrob Chemother 45:583-590
62. Petrella S, Cambau E, Chauffour A, Andries K, Jarlier V, Sougakoff W (2006) Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria. Antimicrob Agents Chemother 50:2853-2856
63. Primm TP, Andersen SJ, Mizrahi V, Avarbock D, Rubin H, Barry CE III (2000) The stringent response of Mycobacterium tuberculosis is required for long-term survival. J Bacteriol 182:4889-4898
64. Rattan A, Kalia A, Ahmad N (1998) Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives. Emerg Infect Dis 4(2):195-209
65. Reynolds RC, Bansal N, Rose J, Friedrich J, Suling WJ, Maddry JA (1999) Ethambutol-sugar hybrids as potential inhibitors of mycobacterial cell-wall biosynthesis. Carbohydr Res 317:164-179
66. Rodriguez JC, Ruiz M, Climent A, Royo G (2001) In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. Int J Antimicrob Agents 17:229-231
67. Ruiz-Serrano MJ, Alcala L, Martinez L, Diaz M, Marin M, Gonzalez-Abad MJ, Bouza E (2000) In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs. Antimicrob Agents Chemother 44:2567-2568
68. Russell DG (2001) Mycobacterium tuberculosis: here today, and here tomorrow. Nat Rev Mol Cell Biol 2:569-577
69. Shafii B, Amini M, Akbarzadeh T, Shafiee A (2008) Synthesis and antitubercular activity of N3,N5-diaryl-4-(5-arylisoxazol-3-yl)-1,4- dihydropyridine-3,5-dicarboxamide. J Sci 19(4):323-328
70. Sirgel FA, Donald PR, Odhiambo J, Githui W, Umapathy KC, Paramasivan CN, Tam CM, Kam KM, Lam CW, Sole KM, Mitchison DA (2000) A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother 45:859-870
71. Smith CV, Huang CC, Miczak A, Russell DG, Sacchettini JC, Honer zu Bentrup K (2003) Biochemical and structural studies of malate synthase from Mycobacterium tuberculosis. J Biol Chem 278:1735-1743
72. Smith CV, Sharma V, Sacchettini JC (2004) TB drug discovery: addressing issues of persistence and resistance. Tuberculosis 84:45-55
73. Snider DE (1994) Tuberculosis: the world situation. History of the disease and efforts to combat it. In: Porter JDH, McAdam KPWJ (eds) Tuberculosis: back to the future. Wiley, New York, pp 14-31
74. Somoskovi A, Parsons LM, Salfinger M (2001) The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respir Res 2:164-168
75. Stahlmann R, Lode H (1999) Toxicity of quinolones. Drugs 58(Suppl 2):37-42
76. Sullivan EA, Kreiswirth BN, Palumbo L, Kapur V, Musser JM, Ebrahimzadeh A, Frieden TR (1995) Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet 345:1148-1150
77. Sulochana S, Rahman F, Paramasivan CN (2005) In vitro activity of fluoroquinolones against Mycobacterium tuberculosis. J Chemother 17:169-173
78. Sun Z, Zhang Y (1999) Antituberculosis activity of certain antifungal and antihelmintic drugs. Tuber Lung Dis 79:319-320
79. Temple ME, Nahata MC (1999) Rifapentine: its role in the treatment of tuberculosis. Ann Pharmacother 33(11):1202-1210
80. Teodori E, Dei S, Scapecchi S, Gualtieri F (2002) The medicinal chemistry of multidrug resistance (MDR) reversing drugs. Il Farmaco\ 57:385-415
81. Trivedi AR, Siddiqui AB, Shah VH (2008) Design, synthesis, characterization and antitubercular activity of some 2-heterocycle-substituted phenothiazines. ARKIVOC ii:210-217
82. Wayne LG, Sohaskey CD (2001) Non replicating persistence of Mycobacterium tuberculosis. Annu Rev Microbiol 55:139-163
83. Weil DEC (1994) Drug supply: meeting a global need. In: McAdam KPWJ, Porter JDH (eds) Tuberculosis: back to the future. Wiley, New York, pp 123-143
84. WHO (2004) Tuberculosis Fact Sheet. http://www.who.int/mediacentre/ factsheets/fs104/en/
85. Willmott CJ, Critchlow SE, Eperon IC, Maxwell A (1994) The complex of DNA gyrase and quinolone drugs with DNA forms a barrier to transcription by RNA polymerase. J Mol Biol 242:351-363
86. Yew WW, Kwan SY, Ma WK, Lui KS, Suen HC (1990) Ofloxacin therapy of Mycobacterium fortuitum infection: further experience. J Antimicrob Chemother 25:880-881
87. Zhanel GG, Hoban DJ, Schurek K, Karlowsky JA (2004) Role of efflux mechanisms on fluoroquinolone resistance in Streptococcus pneumoniae and Pseudomonas aeruginosa. Int J Antimicrob Agents 24:529-535
88. Zhang Y (2005) The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol 45:529-564